Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Japan Generic Market Crosses 1 Trillion Yen Mark in 2019: Fuji Keizai
April 6, 2020
- Denka to Resume Production of Compound for Avigan
April 3, 2020
- Alfresa Allies with Cell Therapy Startup; Possible Tripartite Collaboration with Rohto
April 3, 2020
- Takeda Launches Dedicated COVID-19 Website to Inform of Product Supply, R&D Status
April 3, 2020
- Eisai, Seikagaku Pair Up for Osteoarthritis Drug in China
April 2, 2020
- Amgen Kicks Off Stand-Alone Biz in Japan, Eyes Simultaneous Launch of Full Pipeline
April 2, 2020
- Pfizer Pausing Global Trial Recruitments, but Not in Japan
April 2, 2020
- Daiichi Sankyo Gets License to Ultragenyx’s Gene Therapy Manufacturing Techs
April 2, 2020
- Adcetris plus Chemo Gets EU Panel OK for Front-Line Use: Takeda
April 2, 2020
- Chugai Maps Out Digital Vision for 2030 Aiming at Value Chain Optimization, Novel Drug Discovery
April 2, 2020
- Takeda Introduces Claw-Back Policy for Executives Liable for Business Loss, Misconducts
April 2, 2020
- Post-Promotion Guidelines - 2: Takeda Evaluating “Non-Sales” Factors through Quality Conversations with Bosses
April 1, 2020
- Myovant Licenses European Rights for Relugolix Combo to Gedeon Richter
April 1, 2020
- SanBio Ties Up with China’s Ocumension for Stem Cell Therapies for Eyes
April 1, 2020
- Shionogi Files Xofluza for Post-Exposure Prophylaxis in Taiwan
April 1, 2020
- Fujifilm Launches Avigan Trial with Completion Eyed in June; Sanofi Too to Test Kevzara in Japan
April 1, 2020
- Astellas Suspends Launch of New Clinical Studies in Virus-Hit Countries
April 1, 2020
- Eiken’s Novel Coronavirus Detection Reagent Kit Approved, with Launch Planned in Mid-April
April 1, 2020
- Shionogi Hooks Up with China’s Biggest Insurance Group, Eyes RWD-Based Drug Development
March 31, 2020
- Ono Expands I/O Collaboration with Swiss Firm Numab
March 31, 2020
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…